Virtual Library

  • +

    IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC (ID 278)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 5
    • +

      IS02.01 - Opening Remarks (ID 4309)

      10:30 - 11:30  |  Presenting Author(s): Masahiro Tsuboi

      • Abstract

      Abstract not provided

    • +

      IS02.02 - Current Strategies for IO Therapy for Unresectable Stage III NSCLC (ID 4310)

      10:30 - 11:30  |  Presenting Author(s): Glenwood Dillon Goss

      • Abstract

      Abstract not provided

    • +

      IS02.03 - Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC (ID 4311)

      10:30 - 11:30  |  Presenting Author(s): Suresh Senan

      • Abstract

      Abstract not provided

    • +

      IS02.04 - Defining the Role of Immunotherapy in the Treatment of ES-SCLC (ID 4312)

      10:30 - 11:30  |  Presenting Author(s): Myung-Ju Ahn

      • Abstract

      Abstract not provided

    • +

      IS02.05 - Emerging Biomarkers in SCLC (ID 4313)

      10:30 - 11:30  |  Presenting Author(s): Charles M. Rudin

      • Abstract

      Abstract not provided

  • +

    IS03 - Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (ID 279)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 4
    • +

      IS03.01 - Welcome and Introduction (ID 4315)

      11:45 - 12:45  |  Presenting Author(s): Tony S. Mok

      • Abstract

      Abstract not provided

    • +

      IS03.02 - Evolving Challenges for the Treatment of Advanced NSCLC (ID 4316)

      11:45 - 12:45  |  Presenting Author(s): Tony S. Mok

      • Abstract

      Abstract not provided

    • +

      IS03.03 - Emerging ADC Targets for the Treatment of Late-Line NSCLC (ID 4317)

      11:45 - 12:45  |  Presenting Author(s): Pasi Antero Jänne

      • Abstract

      Abstract not provided

    • +

      IS03.04 - ADC Therapies as Targeted Treatment Options in Patients With Advanced NSCLC (ID 4318)

      11:45 - 12:45  |  Presenting Author(s): James Chih-Hsin Yang

      • Abstract

      Abstract not provided

  • +

    IS04 - Industry Symposium Sponsored by Lilly Oncology: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (ID 281)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 6
    • +

      IS04.01 - Chair’s Welcome (ID 4320)

      13:00 - 14:00  |  Presenting Author(s): Koichi Goto

      • Abstract

      Abstract not provided

    • +

      IS04.02 - Introduction to the Topic - A Brief Overview of the 15-Year Journey of Biomarker Driven Management of NSCLC (ID 4321)

      13:00 - 14:00  |  Presenting Author(s): Koichi Goto

      • Abstract

      Abstract not provided

    • +

      IS04.03 - Developing Best Practices for the Accurate Diagnosis and Treatment of All Patients With NSCLC - Practical Tips on Optimising Diagnostic Capabilities in the Clinic (ID 4322)

      13:00 - 14:00  |  Presenting Author(s): Herbert H Loong

      • Abstract

      Abstract not provided

    • +

      IS04.04 - The Roles of the Oncologist and Pathologist in Providing an Actionable Diagnosis - Discuss the Role of the Tumour Board / MDT in Implementing Precision Medicine (ID 4323)

      13:00 - 14:00  |  Presenting Author(s): Fernando Lopez-Rios

      • Abstract

      Abstract not provided

    • +

      IS04.05 - Gaining Consensus - An Overview of the IASLC, NCCN and ESMO Guidelines for Treating and Testing Patients (ID 4324)

      13:00 - 14:00  |  Presenting Author(s): Giuseppe Curigliano

      • Abstract

      Abstract not provided

    • +

      IS04.07 - Symposium Close (ID 4326)

      13:00 - 14:00  |  Presenting Author(s): Koichi Goto

      • Abstract

      Abstract not provided

  • +

    IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer (ID 282)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 5
    • +

      IS05.01 - Welcome and Introductions (ID 4327)

      14:15 - 15:15  |  Presenting Author(s): Rina Hui

      • Abstract

      Abstract not provided

    • +

      IS05.02 - Frontline Immunotherapy Treatment Options in mNSCLC (ID 4328)

      14:15 - 15:15  |  Presenting Author(s): Rina Hui

      • Abstract

      Abstract not provided

    • +

      IS05.03 - Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer (ID 4329)

      14:15 - 15:15  |  Presenting Author(s): Roy S. Herbst

      • Abstract

      Abstract not provided

    • +

      IS05.04 - Choosing Immunotherapy Alone or in Combination in 1L MNSCLC (ID 4330)

      14:15 - 15:15  |  Presenting Author(s): Corey J. Langer

      • Abstract

      Abstract not provided

    • +

      IS05.05 - Q&A and Closing Remarks (ID 4331)

      14:15 - 15:15  |  Presenting Author(s): Rina Hui, Roy S. Herbst, Corey J. Langer

      • Abstract

      Abstract not provided

  • +

    IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC (ID 283)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 5
    • +

      IS06.01 - Welcome and Introduction (ID 4332)

      15:30 - 16:30  |  Presenting Author(s): Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      IS06.02 - Evolution of the NSCLC Treatment Landscape (ID 4333)

      15:30 - 16:30  |  Presenting Author(s): Yi-long Wu

      • Abstract

      Abstract not provided

    • +

      IS06.03 - Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET? (ID 4334)

      15:30 - 16:30  |  Presenting Author(s): Johan Vansteenkiste

      • Abstract

      Abstract not provided

    • +

      IS06.05 - Rethinking Inflammation to Improve Outcomes in NSCLC: Il-1 as an Emerging Target (ID 4336)

      15:30 - 16:30  |  Presenting Author(s): Yasushi Goto

      • Abstract

      Abstract not provided

    • +

      IS06.07 - Closing (ID 4338)

      15:30 - 16:30  |  Presenting Author(s): Yi-long Wu

      • Abstract

      Abstract not provided

  • +

    IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer (ID 284)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 2
    • +

      IS07.01 - The Past, Present and Future of Biomarker-Driven Advanced NSCLC (ID 4339)

      16:45 - 17:45  |  Presenting Author(s): Benjamin Solomon, Shirish Madhav Gadgeel, Solange Peters

      • Abstract

      Abstract not provided

    • +

      IS07.02 - Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer (ID 4340)

      16:45 - 17:45  |  Presenting Author(s): Ross Soo, Solange Peters, Martin Reck

      • Abstract

      Abstract not provided

  • +

    IS08 - Industry Symposium Sponsored by Janssen Oncology: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (ID 285)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 3
    • +

      IS08.01 - Welcome and Introductions (ID 4341)

      13:00 - 14:00  |  Presenting Author(s): Tetsuya Mitsudomi

      • Abstract

      Abstract not provided

    • +

      IS08.02 - A Light at the End of the Tunnel - Hope for Patients With EGFR Exon20 Insertion Mutations (ID 4342)

      13:00 - 14:00  |  Presenting Author(s): Byoung Chul Cho

      • Abstract

      Abstract not provided

    • +

      IS08.03 - The Dawn of a New Era - Novel Treatments for Patients With TKI Resistant Disease With Common EGFR Mutations (ID 4343)

      13:00 - 14:00  |  Presenting Author(s): Enriqueta Felip

      • Abstract

      Abstract not provided

  • +

    IS09 - Industry Symposium Sponsored by Pfizer Oncology: Expert Question Time: ALK+ NSCLC (ID 286)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 6
    • +

      IS09.01 - Welcome and Introduction (ID 4345)

      13:00 - 14:00  |  Presenting Author(s): Seng Weng Wong

      • Abstract

      Abstract not provided

    • +

      IS09.02 - Navigating Recent Clinical Data for ALK + TKIS (ID 4346)

      13:00 - 14:00  |  Presenting Author(s): Thanyanan Reungwetwattana

      • Abstract

      Abstract not provided

    • +

      IS09.02 - Selecting Treatment and Management of ALK+ NSCLC (ID 4375)

      13:00 - 14:00  |  Presenting Author(s): Nick Pavlakis

      • Abstract

      Abstract not provided

    • +

      IS09.02 - The Importance of Managing CNS Disease (ID 4376)

      13:00 - 14:00  |  Presenting Author(s): John Chang

      • Abstract

      Abstract not provided

    • +

      IS09.02 - The Future of ALK+ NSCLC (ID 4378)

      13:00 - 14:00  |  Presenting Author(s): Nir Peled

      • Abstract

      Abstract not provided

    • +

      IS09.04 - Summary, Thank You and Close (ID 4348)

      13:00 - 14:00  |  Presenting Author(s): Seng Weng Wong

      • Abstract

      Abstract not provided

  • +

    IS10 - Industry Symposium Sponsored by Bristol Myers Squibb: Thoracic Cancers, New Developments with IO (ID 287)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 6
    • +

      IS10.01 - Welcome and Introductions (ID 4349)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      IS10.02 - What Is the Role of IO in Non-Metastatic NSCLC? (ID 4350)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel

      • Abstract

      Abstract not provided

    • +

      IS10.03 - IO in the Treatment of Metastatic NSCLC, Where Are We Now? (ID 4351)

      13:00 - 14:00  |  Presenting Author(s): Julie Brahmer

      • Abstract

      Abstract not provided

    • +

      IS10.04 - Non-Metastatic and Metastatic NSCLC Q&A (ID 4352)

      13:00 - 14:00  |  Presenting Author(s): Virginie Westeel, Julie Brahmer

      • Abstract

      Abstract not provided

    • +

      IS10.05 - What Is I-O’s Impact on the Treatment Paradigm for Mesothelioma Patients? (ID 4353)

      13:00 - 14:00  |  Presenting Author(s): Nicolas Girard

      • Abstract

      Abstract not provided

    • +

      IS10.06 - Mesothelioma Q&A and Closing Remarks (ID 4354)

      13:00 - 14:00  |  Presenting Author(s): Nicolas Girard, Virginie Westeel

      • Abstract

      Abstract not provided

  • +

    IS11 - Industry Symposium Sponsored by Amgen Oncology: Advancing the Next Frontier of Innovation in Lung Cancer Therapies (ID 288)

    • Event: WCLC 2020
    • Type: Industry Symposium
    • Track:
    • Presentations: 3
    • +

      IS11.02 - Current Biomarker Landscape in NSCLC (ID 4356)

      13:00 - 14:00  |  Presenting Author(s): Stephen Fox

      • Abstract

      Abstract not provided

    • +

      IS11.03 - Current Unmet Need in KRAS G12C-Mutated NSCLC (ID 4357)

      13:00 - 14:00  |  Presenting Author(s): Koichi Goto

      • Abstract

      Abstract not provided

    • +

      IS11.04 - Emerging Novel Targets for Lung Cancer (ID 4358)

      13:00 - 14:00  |  Presenting Author(s): Julie Brahmer

      • Abstract

      Abstract not provided